Biogen has announced that an arbitration panel has ruled in its favor in its dispute with SmithKline Beecham over the rate of royalties payable from US sales of SB's hepatitis B vaccine, Engerix B.
Biogen licensed its extensive hepatitis B patent portfolio to SB in 1988 for manufacturing and selling HBV vaccines. SB instituted the arbitration in 1993 in a bid to reduce the rate of royalty payments it was obliged to pay to Biogen. Since SB has continued to pay royalties at the disputed rate during the process, Biogen will not receive any extra payments as a result of the arbitration decision.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze